# Baobab AiBIO Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/baobab-aibio-co

- Industry: Pharmaceuticals
- Headquarters: Incheon, South Korea
- Website: www.baobabaibio.com
- Total disclosed funding: $14M
- Latest round: Series A (Mar 15, 2021)
- Investors on record: 7

## About

Established in 2018 and based in Incheon, South Korea, Baobab AiBIO Co., Ltd develops new drugs by synthesizing protein drugs mainly based on quantum mechanics. The company has financial investors like Mirae Asset, Aju IB investment, etc.

The company focuses on developing new drugs using quantum mechanical synthetic protein drug design technology, biological subspace hyperlinking technology, artificial intelligence-based PK prediction, and protein structure-based cryo-electron microscopy drug discovery technology. The pipeline currently under development includes BAB-104, BAB-107, etc.

## Funding rounds

- Series A, Mar 15, 2021, $14M — AJU IB Investment, SL Investment, Mirae Asset Capital, Samho Green Investment, Mirae Asset Venture Investment, LSK Investment, SHIN POONG PHARM. CO.,LTD

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series A
- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series A
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series A
- Samho Green Investment (https://capitalatlas.ai/funds/samho-green-investment) — Series A
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series A
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series A
- SHIN POONG PHARM. CO.,LTD — Series A